Introduction
Aluminum (Al) as a ubiquitous environmental contaminant can cause toxic effects on the brain, bones, liver and kidneys (Crisponi et al., 2013; Silva and Goncalves, 2015) . Al is widely utilized in various fields, such as therapeutic agents, cosmetic and even food additives (Ribes et al., 2008) . In the body, approximately 50-70% of the Al accumulated in the bone which is one of the main target organs of Al toxicity (Li et al., 2011) . Al exposure can result in bone impairment, disrupt bone formation and then cause bone diseases like osteoporosis, osteodystrophy, and osteomalacia (Aaseth et al., 2012) . Among previous studies, there is increasing evidences indicating that oxidative stress and inflammation are two major contributors to the pathogenesis of Alinduced bone toxicity (Cao et al., 2016; Mai et al., 2016) . During exposure, Al can induce the generation of free radicals, enhance lipid peroxidation and promote inflammation expression (Cao et al., 2016; Mai et al., 2016) . Many studies have demonstrated that Al exposure significantly elevated the expression of interleukin (IL)-1β, IL-6 and tumor necrosis factor-alpha (TNF-α) (Justin-Thenmozhi et al., 2018) . Li et al. also found that Al treatment activated caspase-1 and induced IL-1β and IL-18 release . Oxidative stress associated with aging could accelerate bone loss in postmenopausal women (Almeida et al., 2007) . IL-1β, IL-18, IL-6 and TNF-α could stimulate osteoclastogenesis and enhance bone resorption (Huynh et al., 2017; Kwan Tat et al., 2004; Mansoori et al., 2016) . Meanwhile, the inhibition of oxidative stress and inflammation could effectively prevent bone loss https://doi.org/10.1016/j.taap.2018.10.006 Received 22 June 2018; Received in revised form 15 September 2018; Accepted 3 October 2018 (Alexandre et al., 2017; Zhao et al., 2015) . However, the molecular mechanisms of Al-induced bone impairment still remain unclear.
Thioredoxin-interacting protein (TXNIP) is an intracellular endogenous regulator of oxidative stress and inflammation (Du et al., 2018) . Previous studies have demonstrated that under oxidative stress condition, TXNIP could dissociate from thiroredoxin and activate NODlike receptor protein 3 (NLRP3) inflammasome directly (Zhou et al., 2011) . Meanwhile, decreased TXNIP expression could inhibit the activation of NLRP3 inflammasome in vascular dementia (Du et al., 2018) , non-alcoholic fatty liver disease (He et al., 2017a (He et al., , 2017b and neonatal hypoxic-ischemic brain injury (Chen et al., 2018) . NLRP3 inflammasome, an important member of the nucleotide-binding domain (NOD)-like receptor family, is composed by NLRP3, apoptotic speck protein (ASC) and pro-caspase-1. It has been reported that NLRP3 inflammasome could regulate the expression of IL-1β and IL-18 (Schroder and Tschopp, 2010) . Recently, TXNIP-NLRP3 pathway has been reported participating in the pathology of bone damages. Increased expression of TXNIP played detrimental effects in bone impairment while the activation of NLRP3 inflammasome could contribute to sterile inflammation followed by bone damages (Bonar et al., 2012; Lekva et al., 2012) . However, whether TXNIP-induced NLRP3 inflammasome activation participated in Al-induced bone impairment is still unclear.
Nicotinamide mononucleotide (NMN) is an intermediate of nicotinamide adenine dinucleotide (NAD + ) biosynthesis (Wei et al., 2017) .
Many studies have demonstrated that administration of NMN was an effective therapy to improved intracellular NAD + levels (Wei et al., 2017; Zhou et al., 2016) . Wang et al. found that NMN significantly increased intracellular NAD + levels and protected against beta-amyloid-induced cognitive impairment and neuronal death . Increased NAD + alleviated pro-inflammatory cytokine-mediated impairment of islet function (Caton et al., 2011) . In addition, replenishment of NAD + also attenuated brain injury induced by intracerebral hemorrhage (Wei et al., 2017) . Previous study also demonstrated that decreased intracellular NAD + levels is also associated with the declined osteoblastogenesis (He et al., 2017a (He et al., , 2017b . Therefore, NMN supplement may be an effective therapeutic agent for the treatment of Alinduced bone impairment. However, the molecular mechanisms of how NMN protected against Al-induced bone impairment remains unknown.
In the present study, we conducted to investigate whether replenishment NMN have protective effects on Al-induced bone impairment and to explore whether NMN could protect against Al-induced bone damages via TXNIP-NLRP3 inflammasome pathway.
Materials and methods

Chemicals
NMN (purity > 98%) was purchased from Bontac-Biotech Synthesis Corp. (Shenzhen, China). Aluminum trichloride (AlCl 3 , purity > 98%) was purchased from Sangon Biotech (Shanghai, China). Antibodies against TXNIP, NLRP3, ASC and Casp-1 p20 were purchased from Abcam (Cambridge, USA). Antibodies against IL-1β, IL-18 and β-actin were purchased from Cell Signaling Technology (Beverly, USA).
Animal and treatment
Male Sprague-Dawley rats (3-weeks-old) were obtained from the Experimental Animal Center of Shanghai Jiao tong University School of Medicine and housed at a maintained temperature (23 ± 1°C) and humidity (55 ± 5%) in a 12/12-h light/dark cycle. Food and water were available ad libitum. All animal operative protocols and procedures were approved by Shanghai Jiao tong University School of Medicine Protocol Management and Review Committee. After 7-day acclimatization, the rats were randomly divided into 3 groups: Control group, AlCl 3 group, AlCl 3 + NMN group. The rats in AlCl 3 and AlCl 3 + NMN groups were exposed to AlCl 3 10 mg/L in drinking water for 12 weeks. The rats in AlCl 3 + NMN group received NMN (20 mg/kg) by intraperitoneally injection in the last 4 weeks. After 12 weeks treatment, the rats were sacrificed. The serum and the femurs were obtained and stored at −80°C for further analysis.
Micro-CT
The left femur was fixed in 4% paraformaldehyde and then scanned with the GE Healthcare Locus SP micro-CT (GE Healthcare, USA) (Zhao et al., 2015) . The explore reconstruction utility software (GE Healthcare, USA) was used for three-dimensional reconstruction and data processing. The bone mineral density (BMD), bone volume fraction (BVF), trabecular thickness, trabecular number, and trabecular spacing of femurs were assessed to evaluate bone quality of femurs.
Antioxidant enzymes assay
Femurs were collected and homogenized in ice-cold phosphate buffered saline (PBS), and then centrifuged for 15 min at 12,000 rpm at 4°C. The supernatants were collected and used for the analysis. The activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-P X ) catalase (CAT) and the levels of malondialdehyde (MDA) were determined using commercial kits (Nanjing Jiancheng Bioengineering Institute, China). All assays were performed according to the manufacturer's instructions.
Western blot analysis
The total proteins of femurs and MC3T3-E1 cells were extracted. The proteins from the femurs and MC3T3-E1 cells were quantified by BCA protein assay kit (Beyotime Institute of Biotechnology, China). The proteins were separated on 8-10% SDS-PAGE, and then transferred onto nitrocellulose membranes. After incubated with primary antibodies overnight at 4°C, the nitrocellulose membranes were incubated with the corresponding secondary antibody conjugated with horseradish peroxidase. The relative expression levels were normalized to β-actin. The protein band density was obtained with Odyssey Imaging System.
Quantitative real-time PCR
Total RNA was extracted by Trizol reagent (Invitrogen, USA) from the femurs. Real-time quantitative PCR was performed to analyse relative levels of NLRP3 and TXNIP mRNA expression by using SYBR Green PCR kits (Applied Biosystems) and the StepOnePlus Real-Time PCR System. Each reaction was performed in triplicate. The results were normalized to β-actin expression and calculated using the 2 −ΔΔ Ct method. TXNIP was amplified with forward sequence TAGTGTCCCTG GCTCCAAGAAA and reverse sequence GGATGTTTAGGTCTATCCAGC TCAT; NLRP3 was amplified with forward sequence CCTGACCCAAAC CCACCAGT and reverse sequence TTCTTTCGGATGAGGCTGCTTA; β-actin was amplified with forward sequence ATGGATGACGATATCGC TGC and reverse sequence CTTCTGACCCATACCCACCA.
Elisa analysis
The concentrations of alkaline phosphatase (ALP), bone gammacarboxyglutamic acid protein (BGP), TRACP-5b and C-terminal crosslinking telopeptide of type I collagen (CTX-I) were assayed using ELISA kits (R&D Systems Inc., USA). ELISA kits for IL-1β and IL-18 were purchased from Invitrogen (Invitrogen, USA). NAD + levels in femurs and MC3T3-E1 cells were determined with a NAD + quantification kit (BioVision, USA). All assays were performed according to the manufacturer's instructions.
Cell culture and treatment
MC3T3-E1 cells were purchased from the typical Culture Collections Committee cell library of the Chinese Academy of Sciences (Shanghai, China) and cultured in α-MEM containing 10% fetal bovine serum (FBS) at 37°C in 5% CO 2 -humidified air. MC3T3-E1 Cells were treated with different concentrations of NMN (0.1 mM, 1 mM, 10 mM) and AlCl 3 (0.8 mM) or without AlCl 3 . Each cell experiment was repeated three times.
TXNIP knock-down
The mouse TXNIP-targeting small interfering RNA (siRNA) (Invitrogen, USA) or a control nonspecific siRNA were transfected by Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions. 24 h later, cells were pretreated with 10 mM NMN for 6 h and then exposed to 0.8 mM AlCl 3 for 12 h. Later, the cells were collected for further analysis. Each cell experiment was repeated three times.
Cell viability assay
MC3T3-E1 cells were seeded in a 96-well plate at a density of 5 × 10 3 cells per well and cultured for 24 h. Then cells were treated with different concentrations of NMN for 6 h and 0.8 mM AlCl 3 or without AlCl 3 for another 12 h. Cell viability was examined using a CCK-8 kit (Beyotime Institute of Biotechnology, China) according to the manufacturer's instructions.
Measurement of intracellular ROS
MC3T3-E1 cells were stained with lipophilic probe 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) according to the manufacturer's instructions (Beyotime Institute of Biotechnology, China) to determine the accumulation of intracellular ROS. The cells were treated with different concentrations of NMN for 6 h and 0.8 mM AlCl 3 or without AlCl 3 for another 12 h at 37°C. Then, cells were treated with 5 μM DCFH-DA at 37°C for 30 min. The dye solution was removed and cells were washed twice with PBS. The fluorescence intensity was measured by microplate reader and flow cytometry.
Statistical analysis
Data were analyzed with GraphPad Prism 5 statistic software (La Jolla, CA). Values are presented as the mean ± SEM and analyzed by ANOVA followed by Tukey post-hoc test. P < .05 was considered statistically significant.
Results
NMN treatment protected against AlCl 3 -induced bone impairment
As shown in Fig. 1A , the micro-CT images of the distal femoral diaphysis showed bone structural properties of the trabecular bone in femurs. NMN treatment significantly reversed AlCl 3 -induced intracellular NAD + decrease in femurs (Fig. 1B) . Meanwhile, compared with the AlCl 3 group, NMN supplement also significantly improved BMD, BVF, trabecular thickness and trabecular number as well as decreased trabecular separation (Fig. 1C-G) . Collectively, these results suggested that NMN significantly alleviated AlCl 3 -induced bone impairment.
NMN treatment alleviated AlCl 3 -induced bone loss
We investigated the effects of NMN treatment on bone formation and resorption. As shown in Fig. 2A-D , the serum levels of ALP and BGP were significantly lower while the levels of TRACP-5b and CTX-I were significantly higher in AlCl 3 -treated rats compared with the Control group. Whereas, NMN treatment significantly reduced the levels of TRACP-5b and CTX-I as well as increased the activities of ALP and BGP. These results demonstrated that NMN treatment effectively attenuated AlCl 3 -induced bone loss.
NMN treatment alleviated AlCl 3 -induced oxidative stress in femurs
To assess the effects of NMN on AlCl 3 -induced oxidative stress in the bone. We detected the activities of antioxidative enzymes in femurs. As shown in Fig. 3A-D , compared with the Control group, the activities of the antioxidative enzymes SOD, GSH-Px and CAT were significantly decreased in AlCl 3 group. In contrast, the levels of MDA were significantly elevated. However, NMN treatment preserved the antioxidant activities and decreased MDA content. Taken together, these results demonstrated that treatment with NMN reduced AlCl 3 exposure caused oxidative stress in the bone.
3.1.3. NMN treatment inhibited AlCl 3 -induced inflammation and NLRP3 inflammasome activation in Al-treated rats
To assess the effects of NMN on AlCl 3 -induced bone impairment, we detected the expression of inflammatory associated factors in the serum. As shown in Fig. 4A -B, compared with the Control group, AlCl 3 -treated rats significantly increased IL-18 and IL-1β expression, which were significantly inhibited by NMN treatment. Then, we studied the activation of NLRP3 inflammasome. As shown in Fig. 4C -G, compared with the Control group, treatment with AlCl 3 significantly increased TXNIP, NLRP3, ASC and caspase-1 p20 proteins expression in femurs, interestingly, NMN treatment reduced these increased proteins expression induced by AlCl 3 . The results of TXNIP and NLRP3 mRNA expression confirmed these results (Fig. 4H-I ). These results indicated that NMN may reduce AlCl 3 -induced bone impairment partly by inhibiting NLRP3 inflammasome activation.
NMN treatment enhanced the proliferation and differentiation as well as attenuated AlCl 3 -induced oxidative stress and TXNIP expression in MC3T3-E1 cells
To investigate the molecular mechanisms behind the protection of NMN against AlCl 3 -induced bone damages, an AlCl 3 -treated cell model was established. Firstly, we investigated the effects of AlCl 3 with or without different concentration of NMN (0.1 mM, 1 mM, 10 mM) treatment on MC3T3-E1 cell viabilities. As shown in Fig. 5A , AlCl 3 -induced reduction of MC3T3-E1 cell viability was successfully recovered by NMN treatment. AlCl 3 significantly decreased intracellular NAD+ and increased ROS levels in MC3T3-E1 cells, however, these effects of AlCl 3 were successfully reversed by NMN (Fig. 5B-E) . Furthermore, we found that NMN efficiently increased ALP and BGP activities in AlCl 3 -treated MC3T3-E1 cells (Fig. 5F-G) . Additionally, Western blot analysis showed that the protein levels of TNXIP were significantly increased in AlCl 3 -stimulated MC3T3-E1 cells, whereas NMN treatment successfully decreased TXNIP expression (Fig. 5H) .
NMN treatment inhibited AlCl 3 -induced NLRP3 inflammasome activation in TXNIP pathway in MC3T3-E1 cells
We then determined whether the inhibition of NLRP3 inflammation activation by NMN was associated with suppressing the expression of TXNIP. MC3T3-E1 cells were treated with the specific TXNIP siRNA or the control siRNA before the exposure to AlCl 3 (0.8 mM) and/or NMN (10 mM). As shown in Fig. 6A-F, NMN significantly decreased the expression of NLRP3, Casp-1 (p20), IL-1β and IL-18 induced by AlCl 3 . Meanwhile, TXNIP siRNA effectively induced the same protective effects as NMN on Al-induced NLRP3 inflammasome activation. These results suggest that NMN may reduce AlCl 3 -induced bone damages partly by the suppression of the TXNIP-NLRP3 inflammasome pathway. 
Discussion
Aluminum (Al) is an inorganic contaminant and humans may be exposed to Al in a variety of routes, including drinking water and food (Djouina et al., 2016) . Accumulating evidences have indicated that Al exposure induced oxidative stress and inflammation, resulting in bone impairment and increased risk of osteoporosis (Sun et al., 2016) . NMN is an intermediate of nicotinamide adenine dinucleotide (NAD + ) biosynthesis which exerts numerous biological activities including oxidative stress, inflammation and cell apoptosis (Caton et al., 2011; Wei et al., 2017) . However, the protective effects of NMN on Al-induced bone impairment was poorly understood. In this study, we demonstrated that administration of NMN improved intracellular NAD + levels and protected against Al-induced bone damages. NMN treatment significantly improved BMD and bone structural properties injured by Al exposure. Moreover, NMN remarkably attenuated Al-induced oxidative stress. Furthermore, treatment with NMN decreased the expression of inflammation by inhibiting NLRP3 inflammasome activation. Finally, we found that NMN attenuated Al-induced bone impairment partly through suppressing the TXNIP-NLRP3 inflammasome pathway. NAD + as a pyridine nucleotide is essential for mitochondrial electron transfer chain (Rich, 2003) . Overwhelming evidence has suggested that intracellular NAD + depletion is associated with bone diseases. Li et al. found that during osteogenic differentiation the intracellular NAD + levels were increased (Li et al., 2013) . NAD + is a novel molecule involved in stimulation and maintenance of the osteoblast differentiation (Romanello et al., 2002) . The intracellular levels of NAD + are related to osteogenesis and NAD + depletion is a necessary event for the development of senile osteoporosis (He et al., 2017a (He et al., , 2017b . However, the protective function of NAD + supplement on Al-induced bone impairment was little demonstrated. In our study, we found that Al exposure decreased bone intracellular NAD + levels, BMD and bone structural properties, which were significantly alleviated by NMN-a NAD + supplement. These results suggested that NMN treatment effectively increased intracellular NAD + levels and protected against Alinduced bone impairment. It is widely accepted that increased oxidative stress is closely associated with bone loss (Wang et al., 2012) . Bone formation and bone resorption played a crucial role in the pathogenesis of bone loss. Osteoblasts produced ALP, BGP, and other matrix proteins to form new bones. ALP is a marker of osteoblast differentiation and promoted hydroxyapatite crystal formation (Ravn et al., 2003) . BGP is abundant in bone matrix and is implicated in bone mineralization (Oldknow et al., 2015) . TRACP-5b and CTX-I are markers of osteoclast activity and indicate bone resorption and bone injuries . Al treatment significantly increased oxidative stress and promoted bone resorption (Sun et al., 2016) . Huang et al. also found that Al inhibited osteoblastic proliferation and bone formation (Huang et al., 2017) . Consistent with previous studies, we found that Al exposure decreased the activities of ALP and BGP as well as elevated expression of TRACP5b and CTX-I, whereas NMN treatment significantly reversed these changes. Meanwhile, the levels of MDA were significantly increased while the activities of SOD, CAT and GSH-P X were decreased after Al exposure. NMN treatment remarkably reduced the MDA content and improved the SOD, CAT and GSH-PX activities. These findings indicated that NMN alleviated Al-induced bone loss and oxidative stress. Many studies have shown that NAD + deficiency is associated with NLRP3 inflammasome activation in non-alcoholic fatty liver disease (Zhou et al., 2016 ), Alzheimer's Disease (Pinto et al., 2018) and chronic ethanol exposure stimulated leukocytes (Hoyt et al., 2017) . However, the underlying mechanism of the inhibition of NAD + on NLRP3 inflammasome activation is still unclear. In our study, we found that Al significantly increased the expression of TXNIP, NLRP3, ASC and Casp-1 (p20), resulting in markedly increased IL-1β and IL-18 expression in Al-treated rats, suggesting that TXNIP-NLRP3 pathway may involve in Al-induced bone impairment. However, there are also investigations showing the adverse effects of NAD + in inflammation. Van et al. re- ported that intracellular NAD + levels promoted TNF-α synthesis in immune cells (Van Gool et al., 2009 ). Esposito et al. also found that NAD + depletion reduced the inflammation and alleviated the damages in spinal cord injury (Esposito et al., 2012) . According to our results, treatment with NMN decreased inflammation and inhibited NLRP3 inflammasome activation in Al-treated rats. Nevertheless, more evidence was need to demonstrate the role of NAD + in inflammation and 
NLRP3 inflammasome expression.
To further investigation of the role of TXNIP-NLRP3 pathway in Alinduced bone damages, we used TXNIP siRNA to elucidate the underlying mechanisms in vitro. As expected, TXNIP siRNA treatment significantly inhibited TXNIP expression and prevented Al-induced overexpression of NLRP3 as well as decreasing IL-1β and IL-18 expression. However, NMN exhibited little effects on Al-induced NLRP3, Casp-1 (p20) expression, IL-1β and IL-18 expression in MC3T3-E1 cells transfected with TXNIP siRNA. Consistent with our study, Zhang et al. reported that TXNIP silencing blocked NLRP3 inflammasome activation in fructose-exposed hepatocytes (Esposito et al., 2012) . Constitutively activation of NLRP3 inflammasome induced abnormal skeletal development (Bonar et al., 2012) . Prevented NLRP3 inflammasome activation could inhibit osteoclastogenesis and reduce bone loss (Mansoori et al., 2016) . Meanwhile, silence of TXNIP expression in osteoblast increased the levels of osteocalcin and ALP as well as decreased inflammation expression (Lekva et al., 2012) . Therefore, we speculate that targeting the TXNIP-NLRP3 inflammasome pathway may be an effective therapeutic approach to attenuate Al-induced bone damages.
In summary, NAD + depletion might underlie Al-induced toxicity, whereas NMN may protect against Al-induced bone impairment via inhibiting the TXNIP-NLRP3 inflammasome pathway. Most importantly, our study is the first to report that some protective effects of NMN is mediated by the TXNIP-NLRP3 inflammasome pathway. Taken together, our findings provide a new insight for the application of NMN as an antagonist for Al toxicity.
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